NTI seems significantly undervalued given that completion of Phase II Trials is usually the time for Partnerships,
As well as full blown Take-Overs from Big Pharma Companies are made.
Given that Neurotech Today Announced:
Phase II/III Autism Trial Successfully Meets Primary Endpoint it is even further along.
Given the Markets it can Treat,
such as Autism are worth many many Billions of Dollars,
NTI has a very significant potential upside,
With potential Billions that could be offered in any upcoming deal with Big Pharma.
Phase III is the final step before FDA Approval,
And Sales can begin !!!!
